GLPwatch
Chronic kidney disease
Approved indication
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) is an FDA-approved GLP-1 drug for chronic kidney disease, and multiple studies discuss its pharmacokinetics, safety profile, and role in managing cardiovascular-kidney-metabolic syndrome.
AI summary of the sources below.
How Chronic kidney disease connects
- Drugs Ozempic
- Molecules Semaglutide
- Research 588 papers
Approved GLP-1 drugs (1)
Research (50)
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- The Discovery and Development of Liraglutide and Semaglutide.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
- A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
- Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
- GLP-1 receptor agonists: a review of head-to-head clinical studies.
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies.
- Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.
- Recent updates on GLP-1 agonists: Current advancements & challenges.
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
- Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.
- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
- An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
- Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Common questions
- Which GLP-1 drugs are FDA-approved for Chronic kidney disease?
- Ozempic is FDA-approved for chronic kidney disease.
- Is there research on GLP-1 drugs for Chronic kidney disease?
- GLPwatch tracks 588 research papers on GLP-1 drugs and chronic kidney disease. This research is investigational and does not imply FDA approval.